Chao-Rong Mei1, Meng Luo, Hong-Mei Li, Wen-Jun Deng, Qing-Hua Zhou. 1. Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China;
Abstract
OBJECTIVE: A number of studies have reported the association of "XPA", "XPC", "XPD/ERCC2" gene polymorphisms with lung cancer risk. However, the results were conflict. To clarify the impact of polymorphisms of "XPA", "XPC", "XPD/ERCC2", on lung cancer risk, a meta-analysis was performed in this study. METHODS: The electronic databases PubMed and Embase were retrieved for studies included in this meta-analysis by "XPA", "XPC", "XPD/ERCC2", "lung", "cancer/neoplasm/tumor/carcinoma", "polymorphism" (An upper date limit of October, 31, 2009). A meta-analysis was performed to evaluate the relationship among XPA, XPC and XPD polymorphism and lung cancer risks. RESULTS: A total of 31 publications retrieved from Pubmed and Embase included in this study. XPC A939C CC genotype increased lung cancer risk in total population (recessive genetic model: OR=1.23, 95% CI:1.05-1.44; homozygote comparison: OR=1.21,95%CI:1.02-1.43and CC vs. CA contrast: OR=1.25,95%CI:1.06-1.48), except in Asians. XPD A751C, 751C allele and CC genotype also increased lung cancer risk in total population and in Caucasians (recessive genetic model: Total population: OR=1.20, 95%CI:1.07-1.35). No significant correlation was found between XPD A751C and lung cancer risk in Asians and African Americans. XPD G312A AA genotype increased lung cancer risk in total population, in Asians and Caucasians(recessive genetic model: Total population: OR=1.20, 95%CI: 1.06-1.36). No significant association was found between XPA G23A, XPC C499T, XPD C156A and lung cancer risk. CONCLUSION: Our results suggest that the polymorphisms in XPC and XPD involve in lung cancer risks. XPA polymorphisms is less related to lung cancer risk.
OBJECTIVE: A number of studies have reported the association of "XPA", "XPC", "XPD/ERCC2" gene polymorphisms with lung cancer risk. However, the results were conflict. To clarify the impact of polymorphisms of "XPA", "XPC", "XPD/ERCC2", on lung cancer risk, a meta-analysis was performed in this study. METHODS: The electronic databases PubMed and Embase were retrieved for studies included in this meta-analysis by "XPA", "XPC", "XPD/ERCC2", "lung", "cancer/neoplasm/tumor/carcinoma", "polymorphism" (An upper date limit of October, 31, 2009). A meta-analysis was performed to evaluate the relationship among XPA, XPC and XPD polymorphism and lung cancer risks. RESULTS: A total of 31 publications retrieved from Pubmed and Embase included in this study. XPCA939C CC genotype increased lung cancer risk in total population (recessive genetic model: OR=1.23, 95% CI:1.05-1.44; homozygote comparison: OR=1.21,95%CI:1.02-1.43and CC vs. CA contrast: OR=1.25,95%CI:1.06-1.48), except in Asians. XPDA751C, 751C allele and CC genotype also increased lung cancer risk in total population and in Caucasians (recessive genetic model: Total population: OR=1.20, 95%CI:1.07-1.35). No significant correlation was found between XPDA751C and lung cancer risk in Asians and African Americans. XPDG312A AA genotype increased lung cancer risk in total population, in Asians and Caucasians(recessive genetic model: Total population: OR=1.20, 95%CI: 1.06-1.36). No significant association was found between XPAG23A, XPCC499T, XPDC156A and lung cancer risk. CONCLUSION: Our results suggest that the polymorphisms in XPC and XPD involve in lung cancer risks. XPA polymorphisms is less related to lung cancer risk.
Authors: Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei Journal: Mutat Res Date: 2002-11-30 Impact factor: 2.433
Authors: R Rita Misra; Duminda Ratnasinghe; Joseph A Tangrea; Jarmo Virtamo; Mark R Andersen; Michael Barrett; Philip R Taylor; Demetrius Albanes Journal: Cancer Lett Date: 2003-03-10 Impact factor: 8.679
Authors: Deliang Tang; Stan Cho; Andrew Rundle; Senqing Chen; David Phillips; Jingzhi Zhou; Yanzhi Hsu; Freya Schnabel; Alison Estabrook; Frederica P Perera Journal: Breast Cancer Res Treat Date: 2002-09 Impact factor: 4.872
Authors: Sikandar G Khan; Vanessa Muniz-Medina; Tala Shahlavi; Carl C Baker; Hiroki Inui; Takahiro Ueda; Steffen Emmert; Thomas D Schneider; Kenneth H Kraemer Journal: Nucleic Acids Res Date: 2002-08-15 Impact factor: 16.971
Authors: De-yin Xing; Jun Qi; Wen Tan; Xiao-ping Miao; Gang Liang; Chun-yuan Yu; Wen-fu Lu; Chuan-nong Zhou; Min Wu; Dong-xin Lin Journal: Zhonghua Yi Xue Yi Chuan Xue Za Zhi Date: 2003-02